替诺福韦酯单独与联合恩替卡韦挽救治疗恩替卡韦治疗拉米夫定经治慢性乙型肝炎失败患者疗效比较

摘要/Abstract

摘要： 目的比较替诺福韦酯单药与联合恩替卡韦对恩替卡韦治疗慢性乙型肝炎拉米夫定经治患者仍应答不佳或发生病毒学突破的挽救方案的临床疗效及安全性。方法将80例恩替卡韦序贯治疗仍效果欠佳的拉米夫定经治慢性乙型肝炎患者随机分为单药组40例和联合组40例。单药组给予替诺福韦酯(300 mg/d)替换治疗;联合组使用替诺福韦酯(300 mg/d)和恩替卡韦(0.5 mg/d)治疗。所有患者均治疗48周,检测基线,治疗12、24和48周时病毒学、生化学、血清学指标。比较两组患者上述治疗时间点的完全病毒学应答率、ALT复常率、病毒学突破率和HBeAg血清学转换率及观察药物不良反应。结果单药组患者治疗48周后完全病毒学应答率、ALT复常率、病毒学突破率、HBeAg血清学转换率分别为85.0%(34/40)、76.2%(16/21)、0、13.1%(3/23),联合组分别为87.5%(35/40)、77.3%(17/22)、0、16.0%(41/25),两组比较差异无统计学意义(均P＞0.05)。两组患者耐受性均良好,无一例出现严重不良反应而导致停药。结论对于恩替卡序贯治疗后仍应答不佳或发生病毒学突破的拉米夫定经治慢性乙型肝炎患者,替诺福韦酯单药替换恩替卡韦的挽救治疗仍能有效抑制HBV DNA复制,是一种行之有效的优化治疗方案。

关键词: 慢性乙型肝炎, 恩替卡韦, 治疗失败, 替诺福韦酯, 挽救治疗

Abstract: Objective To compare the clinical efficacy and safety between tenofovir disoproxil fumarate (TDF) monotherapy and TDF-entecavir (ETV) therapy for ETV-refractory chronic hepatitis B (CHB) patients with prior lamivudine (LAM) treatment.Methods Eighty LAM-treated CHB patients with failure of ETV rescue therapy were randomly divided into monotherapy group and combination group. The monotherapy group received TDF (300mg/d) alone for 48 weeks, while the combination group was treated with TDF (300mg/d) plus ETV (0.5mg/d). Assessment of serum hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg), alanine aminotransferase (ALT) and adverse events at week 0, 12, 24 and 48 were performed to analyze therapy efficacy and adverse effects in both groups, respectively. Results After 48-week follow up, the virological response (VR) rate, biochemical response (BR) rate, virologic breakthrough (VB) rate, HBeAg seroconversion rate were 85.0% (34/40), 76.2% (16/21), 0% and 13.1% (3/23) in monotherapy group and 87.5% (35/40), 77.3% (17/22), 0% and 16.0% (4/25) in combination group, respectively (P＞0.05). There were no significant differences in all the monitoring indicators between the two groups. Both groups showed well tolerance with no serious adverse events. Conclusion The TDF monotherapy could be an effective and safe therapeutic strategy for LAM-treated CHB patients who failed to be rescued with ETV therapy.

Key words: Chronic hepatitis B, Entecavir, Suboptimal response, Rescue treatment, Tenofovir disoproxil fumarate

李忠斌, 邵清, 李梵, 李冰, 陈松海, 王春艳, 陈国凤. 替诺福韦酯单独与联合恩替卡韦挽救治疗恩替卡韦治疗拉米夫定经治慢性乙型肝炎失败患者疗效比较[J]. 肝脏, 2016, 21(3): 165-167.

LI Zhong-bin, SHAO Qing, LI Fan, LI Bing, CHEN song-hai, WANG Chun-yan, CHEN Guo-feng. Efficacy comparison of rescue therapies between TDF monotherapy and TDF-ETV combination therapy in CHB patients who failed to be rescued with ETV[J]. Chinese Hepatolgy, 2016, 21(3): 165-167.

参考文献

1 Villet S, Ollivet A, Pichoud C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol, 2007, 46:531-538.
2 参加乙型肝炎耐药讨论会专家.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理. 肝脏,2013,18:1-10.
3 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版). 肝脏,2010,16:1-16.
4 European Association For The Study of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol, 2012,57:167-185.
5 恩替卡韦临床应用专家委员会. 恩替卡韦临床应用专家共识:2015年更新. 中国肝脏病杂志(电子版),2015,7:19-25.
6 Tenney DJ, Pokornowski KA, Baldick CJ, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int, 2008, 2: A88-89.
7 Dupouey J, Gerolami R, Solas C, et al. Hepatitis B virus variant with the a194t substitution within reverse transcriptase before and under adefovir and tenofovir therapy. Clin Res Hepatol Gastroenterol,2012,36:e26-e28.
8 WHO. Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection[EB/OL]. [2015-03-12]. http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/.
9 Hu CY, Liu YM, Liu Y, et al. Pharmacokinetics and tolerability of tenofovir disoproxil fumarate 300 mg once daily: an open-label,single- and multiple-dose study in healthy chinese subjects. Clin Ther,2013,35:1884-1889.
10 Gordon SC, Krastev Z, Horban A, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology, 2013,58:505-513.
11 Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology, 2011,53:62-72.
12 Marcellin P, Gane EJ, Tsai N, et al. Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Hepatology, 2013, 58: 649A.
13 陈芬兰, 艾迎春, 程计林. 替诺福韦与恩替卡韦联合治疗慢性乙型肝炎出现病毒学突破. 肝脏, 2014,19:968-970.
14 Langness JA, Hindman JT, Johnson SC, et al. The frequency of adjusted renal dosing of tenofovir DF and its effects on patient outcomes. J Pharm Pract, 2013,26:397-400.

[1]	钟大明, 蓝柏钊, 欧超兰, 陈开革, 温静, 李嘉丽, 周甦, 莫穆隆, 梁柱石. HBsAg不同载量的HBeAg阳性慢性乙型肝炎对恩替卡韦治疗应答比较[J]. 肝脏, 2020, 25(5): 505-507.
[2]	孙蔚, 杨星. 瞬时弹性成像和声脉冲辐射力成像技术诊断慢性乙型肝炎肝纤维化的价值[J]. 肝脏, 2020, 25(5): 534-535.
[3]	李永涛, 卜贤玉, 李滨. 替诺福韦酯补救治疗对HBV感染肝硬化患者的疗效分析[J]. 肝脏, 2020, 25(4): 400-402.
[4]	卢君瑶, 王登宇, 尹东林, 白玉盘, 许洁. HBV相关肝细胞癌的临床特征及危险因素分析[J]. 肝脏, 2020, 25(3): 285-287.
[5]	沈张平, 王钦君, 季沈杰. 血清miR127-3P与原发性肝癌的相关性研究[J]. 肝脏, 2020, 25(3): 302-305.
[6]	薛宏丽. HBsAg定量在慢性乙型肝炎治疗中的意义[J]. 肝脏, 2020, 25(3): 308-310.
[7]	梅栖榕, 杨丽, 沈毅. 慢性乙型肝炎患者长期服用阿德福韦酯与肾性低磷血症的相关性[J]. 肝脏, 2020, 25(3): 311-313.
[8]	孔媛媛, 魏巍, 单姗, 马红, 欧晓娟, 徐小元, 段钟平, 侯金林, 魏来, 尤红, 贾继东, 中国消除乙肝临床科研平台(CR-HepB)研究组. 乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化[J]. 肝脏, 2020, 25(2): 123-127.
[9]	江海洋, 顾生旺, 刘欢, 姬腾飞, 蒋兆荣, 吴刚, 穆小苏. 基于1 783例慢性乙型肝炎患者长期随访的结果对大幅度提高其临床治愈的思考[J]. 肝脏, 2020, 25(2): 169-171.
[10]	陈攀丽, 唐建荣, 付雪芹, 张逸强, 胡景岚, 吴小力. Hp阳性监测在慢性乙型肝炎合并消化性溃疡患者中的临床意义[J]. 肝脏, 2020, 25(2): 184-185.
[11]	黄菁, 张永臣, 虞玲. 外周血Th17相关炎性因子在慢性乙型肝炎患者接受Peg-IFNα治疗前后的变化及临床意义[J]. 肝脏, 2020, 25(2): 194-196.
[12]	马春明, 张锁才, 史罗明, 吴剑明, 周根法, 郑剑. 慢性乙型肝炎初治后转换恩替卡韦干预的耐药及疗效观察[J]. 肝脏, 2020, 25(2): 208-211.
[13]	张郴华, 钟备, 邓英, 李敏. 慢性乙型肝炎患者HBV核苷(酸)类似物预存耐药基因突变的研究[J]. 肝脏, 2020, 25(1): 39-41.
[14]	李松, 张娟. 替诺福韦酯对乙型肝炎肝硬化患者肝纤维化状态与Th1/Th2型细胞因子的影响研究[J]. 肝脏, 2020, 25(1): 54-55.
[15]	贾瑾堂, 施文娟, 王兆勋, 田鹏飞. 乙型肝炎慢加急性肝衰竭患者血清γ干扰素水平变化的意义[J]. 肝脏, 2020, 25(1): 61-62.